FDA APPROVES TREATMENT FOR HAIRY CELL LEUKEMIA

By | November 5, 2018

Chronic lymphocytic leukemia – Wikipedia

Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Early on there are typically no symptoms. Later non-painful lymph nodes swelling, feeling tired, fever, or weight loss for no clear reason may occur. Enlargement of the spleen and anemia may also occur. It typically worsens gradually.
Continue

Mantle Cell Lymphoma: Practice Essentials, Overview

Feb 11, 2018 · Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles.
Continue

Cancer immunotherapy – Wikipedia

Cancer immunotherapy (sometimes called immuno-oncology) is the artificial stimulation of the immune system to treat cancer, improving on the system’s natural ability to fight cancer.It is an application of the fundamental research of cancer immunology and a growing subspecialty of oncology.It exploits the fact that cancer cells often have molecules on their surface that can be detected by the
Continue

What’s New in Non-Hodgkin Lymphoma Research and Treatment?

Aug 01, 2018 · Research into the causes, prevention, and treatment of non-Hodgkin lymphoma (NHL) is being done in many medical centers throughout the world. Scientists are making a lot of progress in understanding how changes in the DNA inside normal lymphocytes can cause them to develop into lymphoma cells. Once
Continue

Hematopoietic Colony-Stimulating Factors (CSFs) – Medical

For the short acting granulocyte colony-stimulating factors (G-CSFs), Filgrastim-sndz (Zarxio) and filgrastim-aafi (Nivestym) are considered the least costly short acting G-CSFs to Aetna. There are several brands and biosimilars of short acting G-CSFs on the market, including filgrastim (Neupogen
Continue

Media – AstraZeneca US

Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data.
Continue

Interferons – Medical Clinical Policy Bulletins | Aetna

Number: 0404. Policy. Subject to the qualification described below regarding length of treatment and response to treatment, Aetna considers interferon alfa, pegylated interferon, interferon beta, and interferon gamma medically necessary for persons who meet the criteria for each drug specified below.
Continue

Martin S. Tallman | Memorial Sloan Kettering Cancer Center

I am a board-certified hematologist and oncologist and Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center.
Continue

About Immuno-Oncology – Immuno-Oncology News

Immuno-Oncology News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment.
Continue

Rare Disease List – Global Genes

The RARE List™ is comprised of approximately 7,000 different rare diseases and disorders affecting more than 300 million people worldwide. More RARE Facts™ can be found here. We are often asked why some common diseases are included on the RARE List™. The answer is two fold:This is a list of rare diseases defined in the United States where a prevalence of less than 200,000 cases is the
Continue

Category: Uncategorized